502 related articles for article (PubMed ID: 19399246)
1. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Olivares D; Huang X; Branden L; Greig NH; Rogers JT
Int J Mol Sci; 2009 Mar; 10(3):1226-60. PubMed ID: 19399246
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson's Disease and Potential Therapeutic Role of 5' Untranslated Region-Directed Small Molecules.
Cahill CM; Aleyadeh R; Gao J; Wang C; Rogers JT
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33096655
[TBL] [Abstract][Full Text] [Related]
4. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.
Riederer P; Nagatsu T; Youdim MBH; Wulf M; Dijkstra JM; Sian-Huelsmann J
J Neural Transm (Vienna); 2023 May; 130(5):627-646. PubMed ID: 37062012
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
Orimo S
Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
[TBL] [Abstract][Full Text] [Related]
6. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
7. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
8. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
[TBL] [Abstract][Full Text] [Related]
10. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.
Peng Y; Wang C; Xu HH; Liu YN; Zhou F
J Inorg Biochem; 2010 Apr; 104(4):365-70. PubMed ID: 20005574
[TBL] [Abstract][Full Text] [Related]
11. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
[TBL] [Abstract][Full Text] [Related]
12. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Alternatively Spliced α-Synuclein Isoform That Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine Homeostasis.
Vinnakota RL; Yedlapudi D; Manda KM; Bhamidipati K; Bommakanti KT; RangaLakshmi GS; Kalivendi SV
ACS Chem Neurosci; 2018 Dec; 9(12):2948-2958. PubMed ID: 29996045
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
16. Formation and development of Lewy pathology: a critical update.
Jellinger KA
J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
[TBL] [Abstract][Full Text] [Related]
17. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
18. Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy.
Sonustun B; Altay MF; Strand C; Ebanks K; Hondhamuni G; Warner TT; Lashuel HA; Bandopadhyay R
Cells; 2022 Mar; 11(5):. PubMed ID: 35269528
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
20. α-synuclein aggregation and its modulation.
Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
